论文部分内容阅读
目的探讨不同分子亚型浸润性乳腺癌中nm23的表达及其与腋窝淋巴结转移的关系。方法采用免疫组化法检测275例浸润性乳腺癌中nm23的表达水平。结果 nm23在激素受体阳性组、HER2受体阳性组、三阴性乳腺癌组中的表达率分别为84.3%、67.6%和54.5%(P<0.05);nm23的阳性率在无腋窝淋巴结转移组中高于有腋窝淋巴结转移组(P<0.05)。结论在乳腺癌的分子亚型中检测nm23的表达水平可以作为乳腺癌发生、发展的评价指标,更有助于指导其临床治疗和判断预后。
Objective To investigate the expression of nm23 in different subtypes of invasive breast cancer and its relationship with axillary lymph node metastasis. Methods Immunohistochemistry was used to detect the expression of nm23 in 275 cases of invasive breast cancer. Results The positive expression rates of nm23 in hormone receptor positive group, HER2 receptor positive group and triple negative breast cancer group were 84.3%, 67.6% and 54.5%, respectively (P <0.05). The positive rate of nm23 in the cases without axillary lymph node metastasis Moderately higher than axillary lymph node metastasis (P <0.05). Conclusion The detection of nm23 expression in molecular subtypes of breast cancer can be used as an evaluation index for the occurrence and development of breast cancer. It is helpful to guide the clinical treatment and prognosis.